Ligand Pharmaceuticals | LGND - Assets


Ligand Pharmaceuticals reported $1.48B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Amgen USD 90.14B 2.24B Sep/2025
Arrowhead Research USD 1.39B 4.68M Sep/2025
Baxter International USD 21.07B 21M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Gilead Sciences USD 58.53B 2.81B Sep/2025
GlaxoSmithKline GBP 61.34B 2.08B Sep/2025
Glaxosmithkline GBP 82.45B 23.19B Sep/2025
Insmed USD 2.36B 119.12M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Ligand Pharmaceuticals USD 1.48B 528.17M Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Pacira USD 1.3B 239.68M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Veracyte USD 1.37B 23.68M Sep/2025